Please login to the form below

Not currently logged in
Email:
Password:

elbasvir

This page shows the latest elbasvir news and features for those working in and with pharma, biotech and healthcare.

Merck & Co pulls out of hepatitis C R&D as market shrinks

Merck & Co pulls out of hepatitis C R&D as market shrinks

The decision leaves Merck with Zepatier (elbasvir/grazoprevir) as its only product in the HCV category, and one which has made headway in the market with sales leaping ahead to $895m

Latest news

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics